Return to Listing

2 result(s) for ABL001

PI Name Protocol # Title
Michael Heinrich IRB00010537 A Phase I, Multicenter, Open-Label Study of Oral ABL001 in Patients with Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Michael Heinrich STUDY00017418 A Phase 3, Multi-Center, Open-Label Randomized Study of Oral ABL001 Versus Bosutinib in Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or more Tyrosine Kinase Inhibitors
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080